Apontis Pharma provides earnings guidance for the full year 2023. The company expects sales of EUR 36.1 million.
Market Closed -
Other stock markets
|
After market 12:23:36 | |||
8.66 EUR | +3.59% | 8.66 | 0.00% |
04-05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
03-28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+82.32% | 75.07M | |
+32.95% | 700B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B | |
-1.81% | 157B |
- Stock Market
- Equities
- APPH Stock
- News Apontis Pharma AG
- Apontis Pharma Provides Earnings Guidance for the Full Year 2023